The European Medicines Agency (EMA) said on Monday it would no longer post on X and would use rival Bluesky instead, becoming ...
The European Medicines Agency (EMA) has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer ...
Mirati Therapeutics’ hopes of an EU approval for its KRAS inhibitor Krazati in the EU have been thrown into disarray after the EMA’s human medicines committee rejected the drug as a lung ...
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approving ...
GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use ...
As users continue to leave X (formerly Twitter) en masse, many in favor of the newer Bluesky platform, the European Medicines ...
Submission supported by positive results from global, Phase 3 4WHIM clinical trial; U.S. regulatory approval in WHIM syndrome ...
X4 Pharmaceuticals (XFOR) announced that its Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome, a rare ...
London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of ...
Unveiling oncology and non-oncology drug approvals and withdrawals of USFDA and EMA,” published in the January 2025 issue of ...
AMSTERDAM – The European Medicines Agency (EMA) said on Jan 27 that it would no longer post on X and would use rival Bluesky instead, becoming the latest organisation to quit a social media ...